01696 SISRAM MED
- 3.680
- -0.020-0.54%
SISRAM MED News
復銳醫療科技：2023年度報告
Fu Rui Medical Technology (01696) Innovative Hyaluronic Acid Product Profhilo Launched in Hainan
Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
Sisram Medical's Profit Down in Fiscal 2023
Sisram Medical (HKG:1696) recorded a decline in attributable profit for the year ended Dec. 31, 2023, to $31.5 million from $40.2 million during the year-ago period, a Wednesday filing on the Hong Kon
Press Release: Sisram Medical Announces 2023 Annual Results
Sisram Medical Announces 2023 Annual Results PR Newswire HONG KONG, March 20, 2024 Revenues of US$359.3M, with the direct sales portion reaching a record high HONG KONG, March 20, 2024 /PRNewswire
FuRui Medical Technology (01696) will pay a final dividend of HK$0.158 per share
FuRui Medical Technology (01696) announced that it will distribute final shares for the year ended December 31, 2023...
FuRui Medical Technology (01696.HK) annual profit decreased by 17.9% to US$32.9 million
Gelonghui March 20 | FuRui Medical Technology (01696.HK) announced that for the year ended December 31, 2023, the company's revenue was 359.3 million US dollars, an increase of 1.4% over last year's revenue. Gross margin increased from 57.0% in the same period in 2022 to 61.1% in the reporting period. Net cash flow from operating activities for the year was $43.9 million, up 99.4% from last year's net cash flow from operating activities. Profit for the year decreased by 17.9% to $32.9 million from $40.1 million in the same period in 2022. The board of directors decided to pay a final dividend
SISRAM MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21
Sisram FY2023 earnings conference call to be held on March 21, at 8:00 a.m. Eastern Time HONG KONG, March 14, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with
FuRui Medical Technology (01696.HK) plans to hold a board meeting on March 20 to approve the annual results
Gelonghui, March 8, 丨 Fu Rui Medical Technology (01696.HK) issued an announcement. The board of directors announced that the company's board of directors meeting will be held on March 20, 2024 (Wednesday) to consider and approve the Group's annual results for the year ended 31 December 2023, as well as the proposed final dividend (if any), and to deal with other matters.
SISRAM MED: DATE OF BOARD MEETING
Together in Barcelona, FuRui Medical Technology successfully held the 6th Alma Academy
Hong Kong, March 7, 2024 /PRNewswire/ -- March 7, 2024, FuRui Medical Technology Co., Ltd. (“Sisram”; “Company” or “FuRui Medical Technology” for short; stock code: 1696.HK; together with its subsidiaries, the “Group”) today announced that its subsidiary Alma successfully hosted the 6th Alma Academy offline event. The event was held in Barcelona from March 1 to 4, and hosted nearly 400 doctors from 37 countries around the world. FuRui Medical Technology is a global beauty and health group, which is unique
Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Stock Yet As It Plummets 27%
The Sisram Medical Ltd (HKG:1696) share price has fared very poorly over the last month, falling by a substantial 27%. For any long-term shareholders, the last month ends a year to forget by lockin
Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$3.99?
Sisram Medical Ltd (HKG:1696), is not the largest company out there, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$6.00 and falling to the lo
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Medical and aesthetic stocks surged out of the Times Angel (06699) and rose 9.1%, CITIC Securities indicates that sector valuations are already attractive
Jinwu Financial News | The medical and aesthetic sector came out strong, with Times Angel (06699) up 9.1%, FuRui Medical Technology (01696) up 4.84%, Sansheng Pharmaceutical (01530) up 4.03%, Perfect Healthcare (01830) up 3.79%, MODERN DENTAL (03600) up 3.7%, Medical Thinking Health (02138) up 3.28%, and Giant Biotech (02367) up 3.12%. CITIC Securities said that “still water”: the medical and aesthetic industry is being pressured in stages due to multiple factors such as purchasing power and willingness to spend, and the growth rate is slowing down. “Deep flow”: upstream and downstream leaders continue to grow at a high rate, market
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
FuRui Medical Technology (01696.HK): The registration application for Profhilo, an injectable filler product exclusively represented by the company in mainland China, was accepted by the State Drug Administration
Gelonghui November 29丨FuRui Medical Technology (01696.HK) announced that the registration application for Profhilo, an injectable filler product exclusively represented by the company in mainland China, has been accepted by the China Drug Administration (China Drug Administration). This product is a physiological buffer solution of high molecular weight hyaluronic acid (H-HA) and low molecular weight hyaluronic acid (L-HA). It uses NAHYCO's patented blending technology to bring a better anti-aging experience to beauty seekers and patients. The product is distributed exclusively by the company and is already sold in the markets of Israel, India and Hong Kong, China. If this registration application obtains national medicine
Alma, a subsidiary of FuRi Medical Technology, establishes direct sales channels in Japan
Continuing to consolidate market leadership in the Asia-Pacific region, Hong Kong 11/14, 2023/PRNewswire/ -- Fului Medical Technology Co., Ltd. (“Sisram”; “Company” or “FuRei Medical Technology”, stock code: 1696.HK, together with its subsidiaries, collectively known as the “Group”), announced today that Alma Lasers (“Alma”), a subsidiary of the company, has established a new direct sales channel in Japan. This is the sixth direct sales office established by Alma in the Asia-Pacific region so far. Alma is a global leader in the field of energy source medical aesthetic equipment and solutions
Analysis
Price Target
No Data
